Specialised Diagnostic testing for early invasive breast cancer patients

A Contract Award Notice
by SOMERSET NHS FOUNDATION TRUST

Source
Find a Tender
Type
Contract (Services)
Duration
not specified
Value
£163K-£327K
Sector
HEALTH
Published
19 Mar 2026
Delivery
not specified
Deadline
n/a

Related Terms

Location

Musgrove Park Hospital

Geochart for 3 buyers and 1 suppliers

3 buyers

1 supplier

Description

Provision of the Oncotype DX Breast Recurrence Score test.

Total Quantity or Scope

Oncotype DX genomic testing for breast cancer.This notice is confirmation of an award having been made based on a framework agreement and without competition.The lifetime value of the contract is expected to be £326,700.00 call off order.The contract dates are 14 March 2026 to 13 March 2027. This is an existing service with an existing provider.

Award Detail

1 Exact Sciences (London)
  • Num offers: 1
  • Value: £326,700
  • Contractor is an SME.

Award Criteria

Criteria as described in the framework agreement 100.0

CPV Codes

  • 85111800 - Pathology services

Indicators

  • Award on basis of price and quality.

Other Information

This is a Provider Selection Regime (PSR) confirmation of contract award notice. This contract has been awarded under the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.The award decision-makers were Operational Service Manager.There were no known conflicts or potential conflicts of interest of individuals making the decision.

Reference

  • FTS 025052-2026

Domains